Last updated: June 18, 2026
Executive summary: Identify suppliers for IV “Dextrose 10% and Sodium Chloride 0.33%” in plastic containers by anchoring searches to (1) the exact USAN/USP-style name, (2) container type (plastic bag or nested plastic container, depending on labeling), and (3) NDC strength match (Dextrose 10% w/v plus NaCl 0.33% w/v). The most actionable supplier list for procurement and contracting is the set of companies holding the commercial NDCs for that exact composition and container configuration, then cross-checking facility/manufacturing sites for line ownership and substitution risk.
What companies supply dextrose 10% and sodium chloride 0.33% IV in plastic containers?
Featured snippet answer: Suppliers are the manufacturers/labelers listed on the NDCs for the exact product description “Dextrose 10% and Sodium Chloride 0.33%” with plastic container labeling.
How to define “plastic container” for supplier matching
In practice, “plastic container” can mean multiple packaging configurations that still count as compliant IV solution packaging. Procurement teams typically map:
- Plastic bag (most common for premixed dextrose-saline solutions)
- Nested plastic container system (labeling may describe two-layer or nested packaging)
- Single-use unit with leakproof plastic film
The supplier list can change if the search includes containers like glass bottles or non-plastic units, so matching the product labeling language is critical.
Supplier identification workflow used in contracting
- Pull all NDCs that exactly match:
- Active components: Dextrose 10% and Sodium Chloride 0.33%
- Dosage form: Injection
- Packaging: plastic container
- For each NDC, capture:
- Labeler/manufacturer
- Marketing status (active/discontinued)
- Package size
- Manufacturing site when available (site codes vary by data source)
Which NDC labelers manufacture dextrose 10% + sodium chloride 0.33% in plastic bags?
Featured snippet answer: The NDC labelers are the primary supplier candidates for procurement because they control market authorization for that exact dosage and packaging configuration.
What procurement teams should capture per NDC
Build the supplier matrix with these columns:
- NDC
- Labeler (company responsible for listing)
- Strengths (confirm 10% dextrose, 0.33% NaCl)
- Package size and count
- Container description (bag vs nested)
- FDA listing status (if shown in the dataset you’re using)
- Manufacturing site (if disclosed)
Are there multiple suppliers for Dextrose 10% and NaCl 0.33% premix?
Featured snippet answer: Yes, premixed IV solutions often have multiple NDCs and labelers, including alternate manufacturers and private-label supply agreements, but exact multiplicity depends on the specific NDC/container pairing.
Where supplier diversity typically comes from
- Contract manufacturing for the same formulation under different labelers
- Regional distribution contracts using the same underlying product
- Private label arrangements for hospitals, GPOs, and wholesalers
What are the main sourcing channels for this IV solution in the US?
Featured snippet answer: Sourcing typically routes through:
- Wholesalers (primary distribution model for hospitals and IDNs)
- GPO contracts (bundled procurement and pricing)
- Direct hospital purchasing where labelers support procurement portals
- Group purchasing arrangements for steady-volume sites
Commercial practicalities
- Shortages often affect specific NDCs first, not necessarily the entire therapeutic class.
- Substitution depends on whether the alternative has the same strengths and same container configuration (and meets the facility’s interchange policy).
How does container configuration impact supplier availability for dextrose-saline premix?
Featured snippet answer: Packaging constraints can shift availability even when the formulation is the same, because plastic container supply chain bottlenecks (film, ports, seals) and line changeovers can be product- and packaging-specific.
Packaging-specific risks procurement screens for
- Port/closure compatibility
- Handling instructions and bag compatibility with infusion sets
- Storage constraints (some labels specify conditions that affect interchange)
What formulation or USP equivalence points are relevant when switching suppliers?
Featured snippet answer: Switching suppliers is usually lowest risk when the alternative product matches:
- Exact concentrations: Dextrose 10% w/v and NaCl 0.33% w/v
- Total formulation identity: same premix composition and injection characteristics
- Container type: plastic container labeling consistent with facility policy
Typical interchange screening checklist
- Confirm concentrations and labeled volume
- Confirm container material and configuration
- Confirm expiration dating scheme and storage conditions
- Confirm any added components if present (some labels include additional electrolytes or buffers; this is not assumed)
Which suppliers are most likely to support hospital-scale volumes?
Featured snippet answer: The largest candidates are labelers with multiple NDCs for this exact premix and established distribution footprints across major wholesalers and GPOs.
Signals of hospital-scale capability
- Multiple package sizes (commonly common volumes)
- Sustained listing presence (not sporadic)
- Broad wholesaler availability
- Stable manufacturing sites with capacity redundancy
What generic or alternative substitutions exist for dextrose 10% + NaCl 0.33%?
Featured snippet answer: Alternative options are other premixed IV solutions with different saline concentration or different dextrose percentage. These are not substitutes unless the facility approves interchange.
High-level substitution categories procurement uses
- Same dextrose but different saline concentration (e.g., 0.45% vs 0.33%)
- Same saline but different dextrose concentration (e.g., 5% vs 10%)
- Same strengths but different container size or packaging system
What are the regulatory and labeling bases for verifying suppliers?
Featured snippet answer: Supplier verification relies on matching the exact labeled composition to the FDA marketing authorization record for that product’s NDC.
Orange Book relevance
This is an intravenous solution drug product, not typically listed in the Orange Book categories used for drug-substance patents. Verification is done primarily through FDA drug listing/NDC-linked records rather than patent exclusivity.
Key Takeaways
- Supplier selection for Dextrose 10% and Sodium Chloride 0.33% in plastic containers is driven by exact NDC match to the labeled composition and packaging.
- Build a procurement-ready supplier matrix from NDC labelers/manufacturers and verify container type to reduce substitution and formulary compliance risk.
- Container configuration can materially affect availability even when the formulation is constant.
FAQs
1) How do I verify that two products are the same dextrose 10% + NaCl 0.33% IV premix?
Match labeled strengths, volume, and NDC; confirm packaging is labeled as a plastic container configuration.
2) Can I substitute a similar dextrose-saline bag from another supplier?
Only if the substitute matches the exact concentrations and container configuration accepted by the facility.
3) What data fields matter most when sourcing this IV solution?
NDC, labeler/manufacturer, package size, plastic container description, and listing status.
4) Why does supplier availability change for this IV premix?
Packaging supply chain constraints and manufacturing line changes can affect specific NDCs first.
5) What is the fastest way to build a compliant supplier short-list?
Use an NDC-based crosswalk for the exact formulation and packaging, then map to wholesalers and GPO contract availability.
References
- FDA. Drug Products at FDA (NDC drug listing database). Accessed 2026-06-18.
